Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus PLUVICTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus PLUVICTO.
AN-DTPA vs PLUVICTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. After binding, the radioactive isotope lutetium-177 emits beta particles, causing DNA damage and cell death.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is administered intravenously at a dose of 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses, in combination with a gonadotropin-releasing hormone (GnRH) analog or after prior unilateral orchiectomy.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Effective half-life of lutetium-177 is approximately 160 hours (6.67 days), reflecting both physical decay (T1/2 6.647 days) and biological clearance. Clinical context: Due to physical decay, therapeutic radioactivity decreases to <1% after about 45 days.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Primarily renal; approximately 60% of administered radioactivity excreted in urine within 24 hours, with gradual elimination thereafter. Biliary/fecal excretion accounts for <15%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical